Ahmad et al. established that treatment schemes targeting the disruption of EZH2-TERT-lipid metabolism interaction are capable of exhibiting intrinsic specificity for TERT mutant tumors as compared to TERT wild-type GBM tumors (Figure 2) [124]. The gene discussed is TERT; the disease is glioblastoma.